{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T08:41:09Z","timestamp":1793868069206,"version":"4.6.1"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T00:00:00Z","timestamp":1649635200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.atherosclerosis.2022.04.008","type":"journal-article","created":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T20:47:31Z","timestamp":1653079651000},"page":"123-135","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":147,"special_numbering":"C","title":["Lipoprotein(a) measurement issues: Are we making a mountain out of a molehill?"],"prefix":"10.1016","volume":"349","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2229-1120","authenticated-orcid":false,"given":"Florian","family":"Kronenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib1","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-2796.2012.02592.x","article-title":"Lipoprotein(a) - resurrected by genetics","volume":"273","author":"Kronenberg","year":"2013","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib2","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/clinchem\/41.2.246","article-title":"Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a)","volume":"41","author":"Marcovina","year":"1995","journal-title":"Clin. Chem."},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib3","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1172\/JCI113093","article-title":"Lp(a) glycoprotein phenotypes: inheritance and relation to Lp(a)-lipoprotein concentrations in plasma","volume":"80","author":"Utermann","year":"1987","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.atherosclerosis.2022.04.003","article-title":"Lipoprotein(a) beyond the kringle IV repeat polymorphism: thecomplexity of genetic variation in the LPA gene","volume":"349","author":"Coassin","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib5","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1194\/jlr.R067314","article-title":"Structure, function, and genetics of lipoprotein(a)","volume":"57","author":"Schmidt","year":"2016","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib6","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1194\/jlr.M090381","article-title":"A comprehensive map of single base polymorphisms in the hypervariable LPA Kringle IV-2 copy number variation region","volume":"60","author":"Coassin","year":"2019","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib7","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.atherosclerosis.2019.08.019","article-title":"The challenges of measuring Lp(a): a fight against Hydra?","volume":"289","author":"Kronenberg","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib8","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1194\/jlr.RA120000830","article-title":"Generation and characterization of LPA-KIV9, a murine monoclonal antibody binding a single site on apolipoprotein (a)","volume":"61","author":"Gonen","year":"2020","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib9","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/rcm.6883","article-title":"Simultaneous quantitation and size characterization of apolipoprotein(a) by ultra-performance liquid chromatography\/mass spectrometry","volume":"28","author":"Lassman","year":"2014","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib10","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/clinchem\/hvaa324","article-title":"Development of an LC-MS\/MS proposed candidate reference method for the standardization of analytical methods to measure lipoprotein(a)","volume":"67","author":"Marcovina","year":"2021","journal-title":"Clin. Chem."},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib11","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/clinchem\/hvaa239","article-title":"Towards an SI-traceable reference measurement system for seven serum apolipoproteins using bottom-up quantitative proteomics: conceptual approach enabled by cross-disciplinary\/cross-sector collaboration","volume":"67","author":"Cobbaert","year":"2021","journal-title":"Clin. Chem."},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib12","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1172\/JCI119055","article-title":"Kringle-containing fragments of apolipoprotein(a) circulate in human plasma and are excreted into the urine","volume":"98","author":"Mooser","year":"1996","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib13","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1161\/01.ATV.16.8.905","article-title":"Urinary excretion of apo(a) fragments. Role in apo(a) catabolism","volume":"16","author":"Kostner","year":"1996","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib14","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1038\/ki.1997.503","article-title":"Increased plasma concentrations of LDL-unbound apo(a) in patients with end-stage renal disease","volume":"52","author":"Trenkwalder","year":"1997","journal-title":"Kidney Int."},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib15","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1093\/clinchem\/46.12.1956","article-title":"Use of a reference material proposed by the international federation of clinical chemistry and laboratory medicine to evaluate analytical methods for the determination of plasma lipoprotein(a)","volume":"46","author":"Marcovina","year":"2000","journal-title":"Clin. Chem."},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib16","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1093\/eurheartj\/ehx174","article-title":"A novel but frequent variant in LPA KIV-2 is associated with a pronounced Lp(a) and cardiovascular risk reduction","volume":"38","author":"Coassin","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib17","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.jacc.2021.05.037","article-title":"Frequent LPA KIV-2 variants lower lipoprotein(a) concentrations and protect against coronary artery disease","volume":"78","author":"Schachtl-Riess","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib18","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1194\/jlr.M076232","article-title":"A genome-wide association meta-analysis on lipoprotein (a) concentrations adjusted for apolipoprotein (a) isoforms","volume":"58","author":"Mack","year":"2017","journal-title":"JLR (J. Lipid Res.)"},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib19","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13073-020-00771-0","article-title":"Investigation of a nonsense mutation located in the complex KIV-2 copy number variation region of apolipoprotein(a) in 10,910 individuals","volume":"12","author":"Di Maio","year":"2020","journal-title":"Genome Med."},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib20","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/cvr\/cvu107","article-title":"Lipoprotein(a) concentrations, apolipoprotein(a) phenotypes and peripheral arterial disease in three independent cohorts","volume":"103","author":"Laschkolnig","year":"2014","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib21","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/BF00220066","article-title":"The apolipoprotein(a) gene: a transcribed hypervariable locus controlling plasma lipoprotein(a) concentration","volume":"90","author":"Kraft","year":"1992","journal-title":"Hum. Genet."},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib22","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1172\/JCI115248","article-title":"Molecular basis of apolipoprotein (a) isoform size heterogeneity as revealed by pulsed-field gel electrophoresis","volume":"87","author":"Lackner","year":"1991","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib23","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.jacl.2018.07.003","article-title":"Relationship of lipoprotein(a) molar concentrations and mass according to lipoprotein(a) thresholds and apolipoprotein(a) isoform size","volume":"12","author":"Tsimikas","year":"2018","journal-title":"J. Clin. Lipidol"},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib24","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1373\/clinchem.2009.142810","article-title":"Seven direct methods for measuring HDL and LDL cholesterol compared with ultracentrifugation reference measurement procedures","volume":"56","author":"Miller","year":"2010","journal-title":"Clin. Chem."},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib25","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.atherosclerosis.2019.08.015","article-title":"Comparison of lipoprotein(a) serum concentrations measured by six commercially available immunoassays","volume":"289","author":"Scharnagl","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib26","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1194\/jlr.P066258","article-title":"Population and assay thresholds for the predictive value of lipoprotein (a) for coronary artery disease: the EPIC-Norfolk Prospective Population Study","volume":"57","author":"Verbeek","year":"2016","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib27","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib28","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1001\/jamacardio.2018.1470","article-title":"Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a mendelian randomization analysis","volume":"3","author":"Burgess","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib29","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/j.1523-1755.2004.00418.x","article-title":"The apolipoprotein(a) size polymorphism is associated with nephrotic syndrome","volume":"65","author":"Kronenberg","year":"2004","journal-title":"Kidney Int."},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib30","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1161\/ATVBAHA.120.315291","article-title":"Lp(a) (Lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: new insights from a large national biobank","volume":"41","author":"Patel","year":"2021","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib31","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1016\/S0022-2275(20)32100-3","article-title":"Preparation of a stable fresh frozen primary lipoprotein[a] (Lp[a]) standard","volume":"40","author":"Kostner","year":"1999","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib32","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1523-1755.2004.00737.x","article-title":"Lipoprotein(a)- and low-density lipoprotein-derived cholesterol in nephrotic syndrome: impact on lipid-lowering therapy?","volume":"66","author":"Kronenberg","year":"2004","journal-title":"Kidney Int."},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib33","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.016318","article-title":"Low-Density lipoprotein cholesterol corrected for lipoprotein(a) cholesterol, risk thresholds, and cardiovascular events","author":"Willeit","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib34","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","article-title":"Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome","volume":"75","author":"Bittner","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2021.100053","article-title":"Novel method for quantification of lipoprotein(a)-cholesterol: implications for improving accuracy of LDL-C measurements","volume":"62","author":"Yeang","year":"2021","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib36","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s11745-002-0915-1","article-title":"Issues concerning the monitoring of statin therapy in hypercholesterolemic subjects with high plasma lipoprotein(a) levels","volume":"37","author":"Scanu","year":"2002","journal-title":"Lipids"},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib37","first-page":"353","article-title":"Plasma lipoprotein(a) levels and LDL-cholesterol lowering response to statin therapy in patients with heterozygous familial hypercholesterolemia","volume":"36","author":"Miltiadous","year":"2006","journal-title":"Ann. Clin. Lab. Sci."},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib38","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1093\/eurheartj\/ehs344","article-title":"Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study","volume":"34","author":"Hopewell","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib39","article-title":"Assessing the accuracy of estimated lipoprotein(a) cholesterol and lipoprotein(a)-free low-density lipoprotein cholesterol","author":"Zheng","year":"2022","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib40","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S2213-8587(16)30042-0","article-title":"High lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: a prospective cohort study","volume":"4","author":"Langsted","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib41","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1373\/clinchem.2019.306738","article-title":"Effect of lipoprotein(a) on the diagnosis of familial hypercholesterolemia: does it make a difference in the clinic?","volume":"65","author":"Chan","year":"2019","journal-title":"Clin. Chem."},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib42","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0021-9150(92)90271-H","article-title":"Lipoprotein(a) at birth, in blacks and whites","volume":"92","author":"Rifai","year":"1992","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib43","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1542\/peds.89.3.401","article-title":"Early expression of the apolipoprotein (a) gene: relationships between infants' and their parents' serum apolipoprotein (a) levels","volume":"89","author":"Wang","year":"1992","journal-title":"Pediatrics"},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib44","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1210\/clinem\/dgab734","article-title":"Lipoprotein(a) levels at birth and in early childhood: the COMPARE study","volume":"107","author":"Strandkjaer","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib45","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.atherosclerosis.2022.03.004","article-title":"Lipoprotein(a) levels from childhood till adulthood: data in nearly 3,000 children who visited a pediatric lipid clinic","volume":"349","author":"de Boer","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib46","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1093\/eurheartj\/ehz310","article-title":"Statin therapy increases lipoprotein(a) levels","volume":"41","author":"Tsimikas","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib47","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.atherosclerosis.2019.07.001","article-title":"Statin treatment increases lipoprotein(a) levels in subjects with low molecular weight apolipoprotein(a) phenotype","volume":"289","author":"Yahya","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib48","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S0140-6736(18)31652-0","article-title":"Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials","volume":"392","author":"Willeit","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib49","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1161\/CIRCULATIONAHA.113.004406","article-title":"Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER trial (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin)","volume":"129","author":"Khera","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib50","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/eurjpc\/zwab171","article-title":"Statin therapy and lipoprotein(a) levels: a systematic review and meta-analysis","volume":"29","author":"de Boer","year":"2022","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib51","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/aje\/kwp043","article-title":"Lipid changes during the menopause transition in relation to age and weight: the Study of Women's Health across the Nation","volume":"169","author":"Derby","year":"2009","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib52","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jacl.2017.10.024","article-title":"Temporal variability in lipoprotein(a) levels in patients enrolled in the placebo arms of IONIS-APO(a)Rx and IONIS-APO(a)-LRx antisense oligonucleotide clinical trials","volume":"12","author":"Marcovina","year":"2018","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib53","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0009-8981(95)06070-T","article-title":"Whether, to what degree, and why lipoprotein(a) levels change over time","volume":"238","author":"Glueck","year":"1995","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib54","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.atherosclerosis.2014.01.049","article-title":"Lipoprotein(a): fasting and nonfasting levels, inflammation, and cardiovascular risk","volume":"234","author":"Langsted","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib55","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.atherosclerosis.2022.04.006","article-title":"Non-genetic influences on lipoprotein(a) concentrations","volume":"349","author":"Enkhmaa","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib56","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1093\/clinchem\/38.4.550","article-title":"Effect of sample storage on the assay of lipoprotein(a) by commercially available radial immunodiffusion and enzyme- linked immunosorbent assay kits","volume":"38","author":"Craig","year":"1992","journal-title":"Clin. Chem."},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib57","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1161\/01.CIR.91.5.1403","article-title":"Elevated serum lipoprotein(a) is a risk factor for clinical recurrence after coronary balloon angioplasty","volume":"91","author":"Desmarais","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib58","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/S0022-2275(20)39975-2","article-title":"Effect of sample storage on the measurement of lipoprotein(a), apolipoproteins B and A-IV, total and high-density lipoprotein cholesterol and triglycerides","volume":"35","author":"Kronenberg","year":"1994","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib59","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1161\/01.ATV.16.12.1568","article-title":"Lipoprotein(a) in stored plasma samples and the ravages of time: why epidemiological studies might fail","volume":"16","author":"Kronenberg","year":"1996","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib60","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11789-019-00093-5","article-title":"Prediction of cardiovascular risk by Lp(a) concentrations or genetic variants within the LPA gene region","volume":"14","author":"Kronenberg","year":"2019","journal-title":"Clin. Res. Cardiol. Suppl"},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib61","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.atherosclerosis.2022.04.013","article-title":"Mendelian randomization \u2013 principles and its usage in lipoprotein(a) research","volume":"349","author":"Lamina","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib62","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction","volume":"301","author":"Kamstrup","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib63","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/clinchem\/hvaa247","article-title":"Lipoprotein(a) and cardiovascular disease","volume":"67","author":"Kamstrup","year":"2021","journal-title":"Clin. Chem."},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib64","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.atherosclerosis.2022.04.015","article-title":"Lipoprotein(a) and cardiovascular and valvular diseases: a genetic epidemiological perspective","volume":"349","author":"Arsenault","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib65","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib66","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/joim.12207","article-title":"Genetic determination of lipoprotein(a) and its association with cardiovascular disease. Convenient does not always mean better","volume":"276","author":"Kronenberg","year":"2014","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib67","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1001\/jamacardio.2020.5398","article-title":"Clinical utility of lipoprotein(a) and LPA genetic risk score in risk prediction of incident atherosclerotic cardiovascular disease","volume":"6","author":"Trinder","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib68","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10557-016-6648-3","article-title":"Human genetics and the causal role of lipoprotein(a) for various diseases","volume":"30","author":"Kronenberg","year":"2016","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib69","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s10157-013-0875-8","article-title":"Causes and consequences of lipoprotein(a) abnormalities in kidney disease","volume":"18","author":"Kronenberg","year":"2014","journal-title":"Clin. Exp. Nephrol."},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0272-6386(96)90026-8","article-title":"Lipoprotein(a) in renal disease","volume":"27","author":"Kronenberg","year":"1996","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib71","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/eurjpc\/zwab167","article-title":"Finding very high lipoprotein(a): the need for routine assessment","volume":"29","author":"Nurmohamed","year":"2022","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib72","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jacc.2014.03.061","article-title":"Discrimination and net reclassification of cardiovascular risk with lipoprotein (a): prospective 15-year outcomes in the bruneck study","volume":"64","author":"Willeit","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib73","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.jacc.2012.12.023","article-title":"Extreme lipoprotein(a) levels and improved cardiovascular risk prediction","volume":"61","author":"Kamstrup","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib74","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib75","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41591-021-01634-w","article-title":"Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)","volume":"28","author":"Koren","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib76","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.atherosclerosis.2022.04.020","article-title":"Existing and evolving strategies to lower lipoprotein(a)","volume":"349","author":"Schwartz","year":"2022","journal-title":"Atherosclerosis"},{"issue":"41","key":"10.1016\/j.atherosclerosis.2022.04.008_bib77","first-page":"111","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"2020","author":"Mach","year":"2019","journal-title":"Eur. Heart J."},{"issue":"37","key":"10.1016\/j.atherosclerosis.2022.04.008_bib78","first-page":"1129","article-title":"Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults","volume":"2021","author":"Pearson","year":"2021","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2022.04.008_bib79","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1093\/eurjpc\/zwab180","article-title":"Measuring lipoprotein(a): do it without ifs and buts","volume":"29","author":"Kronenberg","year":"2022","journal-title":"Eur. J. Prev. Cardiol."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002191502200185X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002191502200185X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:51:30Z","timestamp":1758156690000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002191502200185X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":79,"alternative-id":["S002191502200185X"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.04.008","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipoprotein(a) measurement issues: Are we making a mountain out of a molehill?","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}